Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Feb 20, 2018
SOUTH PLAINFIELD, N.J. , Feb. 20, 2018 / PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in relation to the
Additional Formats
Feb 13, 2018
- Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30, 2018
Additional Formats
Feb 09, 2018
SOUTH PLAINFIELD, N.J. , Feb. 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 2:35 pm ET .
Additional Formats
Jan 27, 2018
SOUTH PLAINFIELD, N.J. , Jan. 27, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the
Additional Formats
Jan 23, 2018
SOUTH PLAINFIELD, N.J. , Jan. 23, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that updates and preliminary data from ongoing clinical trials of RG7916, an oral survival motor neuron 2 (SMN2) splicing modifier in SMA patients will be presented at the International
Additional Formats
Jan 08, 2018
-- Preliminary 2017 unaudited total revenues of approximately $195M, a 135% increase vs. 2016 --
-- Full-year 2018 net product revenue guidance of $260M to $295M --
-- Survival data from FIREFISH study in Type 1 SMA patients to be presented at upcoming SMA Congress --
Additional Formats
Jan 05, 2018
SOUTH PLAINFIELD, N.J. , Jan. 5, 2018 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 3, 2018 it approved non-statutory stock options to purchase an aggregate of 33,200 shares of its common stock to seven new employees.
Additional Formats
Jan 03, 2018
SOUTH PLAINFIELD, N.J. , Jan. 3, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 36 th Annual JP Morgan Healthcare Conference on Wednesday, January 10 th at 2:30 pm PT .
Additional Formats
Dec 15, 2017
SOUTH PLAINFIELD, N.J. , Dec. 15, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on December 11, 2017 it approved non-statutory stock options to purchase an aggregate of 10,000 shares of its common stock to two new employees.
Additional Formats
Nov 20, 2017
SOUTH PLAINFIELD, N.J. , Nov. 20, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on November 15, 2017 it approved non-statutory stock options to purchase an aggregate of 61,500 shares of its common stock to eight new employees.
Additional Formats